Pharmacokinetics of cefodizime following single doses of 0.5, 1.0, 2.0, and 3.0 grams administered intravenously to healthy volunteers.Cefodizime is a new expanded-spectrum cephalosporin for parenteral use which possesses a broad antibacterial spectrum and potent antibacterial activity and is stable against most...
In-vitro activity of cefodizime against respiratory pathogensThe in-vitro activity of cefodizime was studied against respiratory pathogens and was compared with the activity of other /J-lactams, ciprofloxacin and erythromycin....
Comparative bacteriostatic and bactericidal activities of cefodizime against borrelia burgdorferi sensu latoThe MIC and MSC (minimum spirocheticidal concentration) and killing rate for Borrelia burgdorferi, the etiological agent of Lyme disease, were assessed for cefodizime in comparison with ceftriaxone, minocycline, azithromycin, roxithromycin, and ciprofloxacin....
In vitro antimicrobial activity evaluation of cefodizime (hr221), a new semisynthetic cephalosporin.Cefodizime (HR221) is a new alpha-methoxyimino cephalosporin developed by Hoechst-Roussel with a reported serum half-life of over 2 h....